PROTECT-CHILD Pediatric Transplant Data Implementation Guide, published by Protect Child. This guide is not an authorized publication; it is the continuous build for version 0.1.0-ci-build built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/protect-child/ and changes regularly. See the Directory of published versions
Worked Example — Liver
Worked Example — Liver
One complete PROTECT-CHILD record, end to end. The Model Maps show each entity alone and the Crosswalk lines up the three representations field by field; this page shows how the resources link together for one patient.
These records are illustrative: they exist to show how the profiles fit together, and are built to exercise the guide rather than to be clinically representative.
REC-1-0001 is Mila, nine years old, at La Paz University Hospital (centre 1), cirrhotic since March 2020. The transplant on 15 August 2023 is the index date every other record is positioned against.
Study centre and patients
The La Paz University Hospital as an Organization, then the two people: the recipient REC-1-0001 and the deceased donor DON-1-0001.
Catalogue entries
Study-wide definitions: the two immunosuppressant medications, the lab test and the instrumental investigation.
Recipient history — primary disease
The cirrhosis that brings her to transplant, as a Condition with the organ in bodySite. It predates every visit in the record.
Pre-transplant episode and transplant admission
One inpatient episode, VIS-1-0001, spanning work-up, surgery and the early post-operative period. Peak PRA is 80%, so rituximab is given while she is waitlisted — not donor-directed, since no organ has been offered — and full HLA typing follows with a negative pre-transplant DSA screen. The transplant itself, a split graft, is one linked set with its duct-to-duct biliary anastomosis and an intra-operative bleed; induction immunosuppression starts the same day. On day 5 she has acute kidney injury, a typed clinical event treated with sixteen days of dialysis.
1-month follow-up visit
VIS-1-0002: vitals, three analytes, a biospecimen for genomic analysis, and maintenance tacrolimus with its trough. EBV DNA at 2,450 copies/mL prompts a liver biopsy — EBER-positive nuclei, no bile duct damage or endothelialitis, so EBV hepatitis rather than rejection — and tacrolimus is cut 0.1 → 0.06 mg/kg in response. Hypertension appears here, on tacrolimus and steroids, and amlodipine starts the same day.
Clinical-event visit — acute rejection episode
VIS-1-0003, unscheduled. The bloods bring her in: ALT 86 → 210 U/L, bilirubin 3.8 mg/dL, GGT 180. The biopsy shows C4d in the portal microvasculature with a de novo class I DSA. Treatment is a three-day methylprednisolone pulse at 10 mg/kg/day.
6-month follow-up visit
VIS-1-0004: abdominal imaging, and the amlodipine reviewed — still running since September.
12-month follow-up visit
VIS-1-0005: vitals with 24-hour ABPM, and the three analytes repeated — creatinine 1.2 → 0.8 mg/dL, albumin 3.4 → 4.2 g/dL, ALT 86 → 31 U/L. Albumin and ALT track the graft; the creatinine tracks renal recovery from the early injury, and at 0.8 is still flagged high for a nine-year-old.